Besivance (Besifloxacin HCl) Patent Expiration, LOE Window & CMS Spending

Besivance (Besifloxacin HCl) by Bausch Health: FDA Orange Book core substance LOE 2031-01-09, 0 AB generics, $7.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN022308 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-01-09
Last Listed Patent or Exclusivity Date2031-01-09
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.0M
2024 Medicare Part D Spend$6.8M
2024 Medicaid Spend$189K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.